{
    "title": "Regeneron sees strong initial demand for higher-dose Eylea",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12701825/Regeneron-beats-quarterly-profit-estimates-eczema-treatment-strength.html",
    "date": "2023-11-02",
    "keywords": [
        "quarter",
        "eylea",
        "regeneron",
        "roy",
        "demand",
        "version",
        "drug",
        "launch",
        "treatment",
        "street",
        "year",
        "company",
        "dose",
        "profit",
        "thursday",
        "eye",
        "growth",
        "competition",
        "rival",
        "approval",
        "call",
        "medicine",
        "executive",
        "marion",
        "august",
        "vabysmo",
        "analyst",
        "bansal",
        "thirdquarter",
        "beat",
        "eczema",
        "dupixent",
        "partner",
        "sanofi",
        "basis",
        "share",
        "companys",
        "revenue",
        "reporting",
        "bengaluru",
        "editing",
        "dasgupta",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}